Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Income towards Parent Company (2020 - 2026)

Climb Bio filings provide 7 years of Income towards Parent Company readings, the most recent being -$13.7 million for Q1 2026.

  • Quarterly Income towards Parent Company rose 33.93% to -$13.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$52.5 million through Mar 2026, up 43.49% year-over-year, with the annual reading at -$59.6 million for FY2025, 19.39% up from the prior year.
  • Income towards Parent Company hit -$13.7 million in Q1 2026 for Climb Bio, up from -$17.5 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$1.7 million in Q1 2024 and bottomed at -$54.9 million in Q2 2024.
  • Average Income towards Parent Company over 5 years is -$13.3 million, with a median of -$8.9 million recorded in 2024.
  • The largest annual shift saw Income towards Parent Company skyrocketed 92.62% in 2024 before it crashed 1145.85% in 2025.
  • Climb Bio's Income towards Parent Company stood at -$8.8 million in 2022, then skyrocketed by 57.1% to -$3.8 million in 2023, then tumbled by 122.37% to -$8.4 million in 2024, then crashed by 108.22% to -$17.5 million in 2025, then rose by 21.6% to -$13.7 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Income towards Parent Company are -$13.7 million (Q1 2026), -$17.5 million (Q4 2025), and -$12.9 million (Q3 2025).